Spruce Biosciences (SPRBD) & The Competition Critical Review

Earnings & Valuation

This table compares Spruce Biosciences and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-0.08
Spruce Biosciences Competitors	$163.24 million	-$11.65 million	-424.47

Spruce Biosciences’ peers have higher revenue, but lower earnings than Spruce Biosciences. Spruce Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 24.8% of shares of all “Biotechnology” companies are held by institutional investors. 6.9% of Spruce Biosciences shares are held by company insiders. Comparatively, 20.8% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Spruce Biosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	N/A	N/A
Spruce Biosciences Competitors	-15,247.28%	32.46%	-33.43%

Volatility and Risk

Spruce Biosciences has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Spruce Biosciences’ peers have a beta of 1.38, indicating that their average stock price is 38% more volatile than the S&P 500.

Summary

Spruce Biosciences beats its peers on 5 of the 8 factors compared.